ReviewMultiple sclerosis international2013
Autoimmune T-cell reactivity to myelin proteolipids and glycolipids in multiple sclerosis.
Review in Multiple sclerosis international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- Myelin-specific IL2 + T-cells are associated with last occurring relapse severity in relapsing-remitting multiple sclerosis.Scientific reports · 2026Article
- Human microbiome-derived peptide affects the development of experimental autoimmune encephalomyelitis via molecular mimicry.EBioMedicine · 2025Article
- Immune checkpoint-based biomarkers for therapeutic response in patients with multiple sclerosis.Frontiers in immunology · 2025Observational
- Understanding the link between neurotropic viruses, BBB permeability, and MS pathogenesis.Journal of neurovirology · 2024Review
- Engineering chimeric autoantibody receptor T cells for targeted B cell depletion in multiple sclerosis model: AnHeliyon · 2023Article
- Molecular mimicry between Zika virus and central nervous system inflammatory demyelinating disorders: the role of NS5 Zika virus epitope and PLP autoantigens.Arquivos de neuro-psiquiatria · 2023Article
- Sphingolipid Players in Multiple Sclerosis: Their Influence on the Initiation and Course of the Disease.International journal of molecular sciences · 2022Review
- Made to Measure: Patient-Tailored Treatment of Multiple Sclerosis Using Cell-Based Therapies.International journal of molecular sciences · 2021Review
- Antigen-Specific Treatment Modalities in MS: The Past, the Present, and the Future.Frontiers in immunology · 2021Review
- HLA Class II Genotype Does Not Affect the Myelin Responsiveness of Multiple Sclerosis Patients.Cells · 2020Article
- Correlation Between Anti-Myelin Proteolipid Protein (PLP) Antibodies and Disease Severity in Multiple Sclerosis Patients With PLP Response-Permissive HLA Types.Frontiers in immunology · 2020Article
- Comparative Analysis of T-Cell Responses to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in Inflammatory Demyelinating Central Nervous System Diseases.Frontiers in immunology · 2020Article
- Multiple Sclerosis: Lipids, Lymphocytes, and Vitamin D.Immunometabolism · 2020Article
- Anti-Myelin Proteolipid Protein Peptide Monoclonal Antibodies Recognize Cell Surface Proteins on Developing Neurons and Inhibit Their Differentiation.Journal of neuropathology and experimental neurology · 2019Article
- Clinical and immunological control of experimental autoimmune encephalomyelitis by tolerogenic dendritic cells loaded with MOG-encoding mRNA.Journal of neuroinflammation · 2019Article
- Antigen-Drug Conjugates as a Novel Therapeutic Class for the Treatment of Antigen-Specific Autoimmune Disorders.Molecular pharmaceutics · 2019Article
- Developmental Changes in Oligodendrocyte Genesis, Myelination, and Associated Behavioral Dysfunction in a Rat Model of Intra-generational Protein Malnutrition.Molecular neurobiology · 2019Article
- Combination therapy with lenalidomide and nanoceria ameliorates CNS autoimmunity.Experimental neurology · 2015Article
- Prolonged Subdural Infusion of Kynurenic Acid Is Associated with Dose-Dependent Myelin Damage in the Rat Spinal Cord.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central nervous system (CNS) myelin, the likely major target of autoimmune attack in multiple sclerosis (MS), contains a number of unique components that are potential targets of the attack. Two classes of molecules that are greatly enriched in CNS myelin compared to other parts of the body are certain types of proteolipids and glycolipids. Due to the hydrophobic nature of both of these classes of molecules, they present challenges for use in immunological assays and have therefore been somewhat neglected in studies of T-cell reactivity in MS compared to more soluble molecules such as the myelin basic proteins and the extracellular domain of myelin oligodendrocyte glycoprotein. This review firstly looks at the makeup of CNS myelin, with an emphasis on proteolipids and glycolipids. Next, a retrospective of what is known of T-cell reactivity directed against proteolipids and glycolipids in patients with MS is presented, and the implications of the findings are discussed. Finally, this review considers the question of what would be required to prove a definite role for autoreactivity against proteolipids and glycolipids in the pathogenesis of MS.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.